In recent years, KMT1A has contributed significantly in the tumorigenesis of myeloma, leukemia (Tran et al., 2013), breast cancer (Yokoyama et al., 2013), colorectal cancer (Yokoyama et al., 2013), non-small cell lung cancer (Liu et al., 2015), and hepatocellular carcinoma (Chiba et al., 2015); thus, it serves as a potential therapeutic target in cancer treatment. The gene discussed is SUV39H1; the disease is plasma cell myeloma.